Technical Analysis for SBTX - Silverback Therapeutics, Inc.

Grade Last Price % Change Price Change
F 34.21 -2.67% -0.94
SBTX closed down 7.67 percent on Monday, April 12, 2021, on 75 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical SBTX trend table...

Date Alert Name Type % Chg
Reversal New Lows Setup Bearish Swing Setup -2.67%
Outside Day Range Expansion -2.67%
Wide Bands Range Expansion -2.67%
Oversold Stochastic Weakness -2.67%
Stochastic Buy Signal Bullish -10.14%
Wide Bands Range Expansion -10.14%
Oversold Stochastic Weakness -10.14%
Bullish Engulfing Bullish -14.71%
NR7 Range Contraction -14.71%
Multiple of Ten Bullish Other -14.71%
Older End-of-Day Signals for SBTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 2 hours ago
3x Volume Pace about 5 hours ago
2x Volume Pace about 5 hours ago
1.5x Volume Pace about 5 hours ago
Down 2 % about 5 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Silverback Therapeutics, Inc. Description

Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was founded in 2016 and is headquartered in Seattle, Washington.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Life Sciences Clinical Medicine Immunology Drugs Treatment Of Cancer Monoclonal Antibody Small Cell Lung Cancer Antibody Hepatitis B Antineoplastic Drugs Tumors Targeted Therapy Serious Diseases Her2 Hepatitis B Virus Fibrosis Linker Chronic Hepatitis B Virus Lung Cancers Small Cell Lung Cancers Viral Infection Viral Infections Hepatitis B Virus Infection Non Small Cell Lung Cancers Tlr8

Is SBTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 63.41
52 Week Low 24.22
Average Volume 246,724
200-Day Moving Average 0.00
50-Day Moving Average 47.33
20-Day Moving Average 47.02
10-Day Moving Average 40.51
Average True Range 4.94
ADX 21.57
+DI 12.87
-DI 28.94
Chandelier Exit (Long, 3 ATRs ) 48.59
Chandelier Exit (Short, 3 ATRs ) 49.18
Upper Bollinger Band 62.15
Lower Bollinger Band 31.90
Percent B (%b) 0.11
BandWidth 64.34
MACD Line -3.21
MACD Signal Line -1.85
MACD Histogram -1.3597
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 43.23
Resistance 3 (R3) 43.86 41.80 41.88
Resistance 2 (R2) 41.80 39.75 41.49 41.43
Resistance 1 (R1) 38.48 38.48 37.45 37.84 40.98
Pivot Point 36.42 36.42 35.90 36.10 36.42
Support 1 (S1) 33.09 34.36 32.06 32.46 29.32
Support 2 (S2) 31.03 33.09 30.72 28.87
Support 3 (S3) 27.71 31.03 28.42
Support 4 (S4) 27.07